Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
45.3 ^USD	+1.98%		-1.93%	-24.71%

23/04	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
22/04	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	17/04	MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	03/04	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	18/03	MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	13/03	MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	03/01	MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target	19/12	MT
Earnings, Interest Rates Cap Wall Street Pre-Bell; Asia Choppy, Europe Up	20/11	MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating	15/11	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating	18/23/18	MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating	18/23/18	MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating	21/23/21	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating	21/23/21	MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating	20/23/20	MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating	13/23/13	MT
HC Wainwright Adjusts Legend Biotech Price Target to $82 From $77, Maintains Buy Rating	06/23/06	MT
William Blair Initiates Legend Biotech at Market Perform	25/23/25	MT
Daiwa Securities Initiates Legend Biotech at Buy Rating	22/23/22	MT
Barclays Adjusts Price Target on Legend Biotech to $90 From $65, Keeps Overweight Rating	19/23/19	MT
RBC Boosts Price Target on Legend Biotech to $83 From $74, Cites Greater Confidence in Manufacturing Progress, Keeps Outperform Rating	19/23/19	MT
BMO Capital Adjusts Price Target on Legend Biotech to $90 From $79, Maintains Outperform Rating	25/23/25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Analyst Reco.

Filters